Search

Your search keyword '"Corey, Kathleen"' showing total 199 results

Search Constraints

Start Over You searched for: Author "Corey, Kathleen" Remove constraint Author: "Corey, Kathleen" Database Unpaywall Remove constraint Database: Unpaywall
199 results on '"Corey, Kathleen"'

Search Results

1. Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis

2. Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD

3. CT Texture Analysis in Nonalcoholic Fatty Liver Disease (NAFLD)

4. Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine

5. Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial

6. Genetic risk factors for NAFLD and clinically significant fibrosis in persons living with HIV

9. American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease

10. Serum Fibroblast Growth Factor-21 Discriminates Between Decompensated Alcohol-Associated Cirrhosis and Severe Alcohol-Associated Hepatitis

11. Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study

12. Non-alcoholic fatty liver disease is not associated with impairment in health-related quality of life in virally suppressed persons with human immune deficiency virus

13. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies

14. Proteomic Analysis of Hepatic Fibrosis in Human Immunodeficiency Virus–Associated Nonalcoholic Fatty Liver Disease Demonstrates Up-regulation of Immune Response and Tissue Repair Pathways

15. OR27-2 Growth Hormone Reduces Hepatic Steatosis, Inflammation and Fibrosis in Adults with Overweight/Obesity and Nonalcoholic Fatty Liver Disease

16. Risk factors for cardiovascular disease among individuals with hepatic steatosis

17. NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?

20. Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

22. Reliability of histologic disease activity measures in non-alcoholic fatty liver disease (NAFLD) and development of an expanded NAFLD activity score

23. Results of the Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study 1.1 on the reproducibility and repeatability of shear-wave and transient elastography in non-alcoholic fatty liver disease

24. Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature

29. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score

34. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD

35. Machine learning enables new insights into genetic contributions to liver fat accumulation

38. Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

39. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD

41. Distinct Hepatic Gene‐Expression Patterns of NAFLD in Patients With Obesity

42. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease

44. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach

46. Growth Hormone Releasing Hormone Reduces Plasma Markers of Immune Activation and Hepatic Immune Pathways in Nonalcoholic Fatty Liver Disease

47. 656 SEDENTARY LIFESTYLE AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK SCORE PREDICT INCIDENT MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH HEPATIC STEATOSIS

48. Expression of IGF-1, IGF-1 Receptor and Growth Hormone Receptor in Hepatic Tissue in Adults Across the Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

50. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease

Catalog

Books, media, physical & digital resources